These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 25163700)

  • 41. Juvenile myelomonocytic leukemia: a report from the 2nd International JMML Symposium.
    Chan RJ; Cooper T; Kratz CP; Weiss B; Loh ML
    Leuk Res; 2009 Mar; 33(3):355-62. PubMed ID: 18954903
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Molecular mechanism and treatment of juvenile myelomonocytic leukemia (JMML)].
    Manabe A
    Rinsho Ketsueki; 2012 Aug; 53(8):729-33. PubMed ID: 22975811
    [No Abstract]   [Full Text] [Related]  

  • 43. Advances in the genetics of high-risk childhood B-progenitor acute lymphoblastic leukemia and juvenile myelomonocytic leukemia: implications for therapy.
    Loh ML; Mullighan CG
    Clin Cancer Res; 2012 May; 18(10):2754-67. PubMed ID: 22589484
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Allogeneic hematopoietic stem cell transplantation for juvenile myelomonocytic leukemia with intestinal Behçet's disease: A case report.
    Liu C; Fu C; Guo X; Rong L; Li J; Fang Y
    Int J Rheum Dis; 2024 Jan; 27(1):e14882. PubMed ID: 37771000
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Juvenile myelomonocytic leukemia displays mutations in components of the RAS pathway and the PRC2 network.
    Caye A; Strullu M; Guidez F; Cassinat B; Gazal S; Fenneteau O; Lainey E; Nouri K; Nakhaei-Rad S; Dvorsky R; Lachenaud J; Pereira S; Vivent J; Verger E; Vidaud D; Galambrun C; Picard C; Petit A; Contet A; Poirée M; Sirvent N; Méchinaud F; Adjaoud D; Paillard C; Nelken B; Reguerre Y; Bertrand Y; Häussinger D; Dalle JH; Ahmadian MR; Baruchel A; Chomienne C; Cavé H
    Nat Genet; 2015 Nov; 47(11):1334-40. PubMed ID: 26457648
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The genomic landscape of juvenile myelomonocytic leukemia.
    Stieglitz E; Taylor-Weiner AN; Chang TY; Gelston LC; Wang YD; Mazor T; Esquivel E; Yu A; Seepo S; Olsen S; Rosenberg M; Archambeault SL; Abusin G; Beckman K; Brown PA; Briones M; Carcamo B; Cooper T; Dahl GV; Emanuel PD; Fluchel MN; Goyal RK; Hayashi RJ; Hitzler J; Hugge C; Liu YL; Messinger YH; Mahoney DH; Monteleone P; Nemecek ER; Roehrs PA; Schore RJ; Stine KC; Takemoto CM; Toretsky JA; Costello JF; Olshen AB; Stewart C; Li Y; Ma J; Gerbing RB; Alonzo TA; Getz G; Gruber T; Golub T; Stegmaier K; Loh ML
    Nat Genet; 2015 Nov; 47(11):1326-1333. PubMed ID: 26457647
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Diagnosis and treatment of juvenile myelomonocytic leukemia in Slovak Republic: novel approaches.
    Fabri O; Horakova J; Bodova I; Svec P; Laluhova Striezencova Z; Bubanska E; Cermak M; Galisova V; Skalicka K; Vaska A; Doczyova D; Panikova A; Sykora T; Adamcakova J; Kolenova A
    Neoplasma; 2019 Sep; 66(5):818-824. PubMed ID: 31129971
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Juvenile myelomonocytic leukemia-A comprehensive review and recent advances in management.
    Gupta AK; Meena JP; Chopra A; Tanwar P; Seth R
    Am J Blood Res; 2021; 11(1):1-21. PubMed ID: 33796386
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Genomic and Epigenomic Landscape of Juvenile Myelomonocytic Leukemia.
    Fiñana C; Gómez-Molina N; Alonso-Moreno S; Belver L
    Cancers (Basel); 2022 Mar; 14(5):. PubMed ID: 35267643
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Molecular assessment of pretransplant chemotherapy in the treatment of juvenile myelomonocytic leukemia.
    Hecht A; Meyer J; Chehab FF; White KL; Magruder K; Dvorak CC; Loh ML; Stieglitz E
    Pediatr Blood Cancer; 2019 Nov; 66(11):e27948. PubMed ID: 31347788
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Gene mutations do not operate in a vacuum: the increasing importance of epigenetics in juvenile myelomonocytic leukemia.
    Flotho C
    Epigenetics; 2019 Mar; 14(3):236-244. PubMed ID: 30773984
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Induced Pluripotent Stem Cells to Model Juvenile Myelomonocytic Leukemia: New Perspectives for Preclinical Research.
    Wehbe Z; Ghanjati F; Flotho C
    Cells; 2021 Sep; 10(9):. PubMed ID: 34571984
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Integrated molecular profiling of juvenile myelomonocytic leukemia.
    Murakami N; Okuno Y; Yoshida K; Shiraishi Y; Nagae G; Suzuki K; Narita A; Sakaguchi H; Kawashima N; Wang X; Xu Y; Chiba K; Tanaka H; Hama A; Sanada M; Ito M; Hirayama M; Watanabe A; Ueno T; Kojima S; Aburatani H; Mano H; Miyano S; Ogawa S; Takahashi Y; Muramatsu H
    Blood; 2018 Apr; 131(14):1576-1586. PubMed ID: 29437595
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A predictive classifier of poor prognosis in transplanted patients with juvenile myelomonocytic leukemia: a study on behalf of the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire.
    Meyran D; Arfeuille C; Chevret S; Neven Q; Caye-Eude A; Lainey E; Petit A; Rialland F; Michel G; Plantaz D; Jubert C; Theron A; Gandemer V; Ouachée-Chardin M; Paillard C; Bruno B; Buchbinder N; Pochon C; Calvo C; Fahd M; Baruchel A; Cavé H; Dalle JH; Strullu M
    Haematologica; 2024 Sep; 109(9):2908-2919. PubMed ID: 38385260
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Droplet digital PCR: An effective method for monitoring and prognostic evaluation of minimal residual disease in JMML.
    Mao S; Lin Y; Qin X; Miao Y; Luo C; Luo C; Wang J; Huang X; Zhu H; Lai J; Chen J
    Br J Haematol; 2024 Jun; 204(6):2332-2341. PubMed ID: 38622924
    [TBL] [Abstract][Full Text] [Related]  

  • 56. CREBBP is a target of epigenetic, but not genetic, modification in juvenile myelomonocytic leukemia.
    Fluhr S; Boerries M; Busch H; Symeonidi A; Witte T; Lipka DB; Mücke O; Nöllke P; Krombholz CF; Niemeyer CM; Plass C; Flotho C
    Clin Epigenetics; 2016; 8():50. PubMed ID: 27158276
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinical characteristics of 15 children with juvenile myelomonocytic leukaemia who developed blast crisis: MDS Committee of Japanese Society of Paediatric Haematology/Oncology.
    Honda Y; Tsuchida M; Zaike Y; Masunaga A; Yoshimi A; Kojima S; Ito M; Kikuchi A; Nakahata T; Manabe A
    Br J Haematol; 2014 Jun; 165(5):682-7. PubMed ID: 24588411
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Management of Two Juvenile Myelomonocytic Leukemia Patients According to Clinical and Genetic Features.
    Tüfekçi Ö; Ören H; Demir Yenigürbüz F; Gözmen S; Karapınar TH; İrken G
    Turk J Haematol; 2015 Jun; 32(2):175-9. PubMed ID: 26316488
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pediatric myelodysplastic syndrome with inflammatory manifestations: Diagnosis, genetics, treatment, and outcome.
    Yanir AD; Krauss A; Stein J; Steinberg-Shemer O; Gilad O; Lotan SN; Dgany O; Krasnov T; Kodman Y; Feuerstein T; Mardoukh J; Fishman H; Geron I; Yacobovich J; Tamary H; Birger Y; Avrahami G; Izraeli S; Birenboim SB
    Pediatr Blood Cancer; 2021 Oct; 68(10):e29138. PubMed ID: 34019335
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Juvenile myelomonocytic leukemia and chronic myelomonocytic leukemia.
    Emanuel PD
    Leukemia; 2008 Jul; 22(7):1335-42. PubMed ID: 18548091
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.